On Monday, Following U.S. Stocks were among the “Top Gainers”: Advaxis, Inc. (NASDAQ:ADXS), Greif, Inc. (NYSE:GEF), ResMed Inc. (NYSE:RMD), Akorn, Inc. (NASDAQ:AKRX)
Advaxis, Inc. (NASDAQ:ADXS), with shares inclined 4.83%, closed at $13.01, hitting new 52-week high of $14.50.
Greif, Inc. (NYSE:GEF), with shares jumped 4.77%, settled at $39.30.
ResMed Inc. (NYSE:RMD), with shares climbed 4.76%, and closed at $71.02, hitting new 52-week high of $71.20.
Akorn, Inc. (NASDAQ:AKRX), surged 4.70%, and closed at $43.22.
Latest NEWS regarding these Stocks are depicted underneath:
Advaxis, Inc. (NASDAQ:ADXS)
Advaxis, Inc. (ADXS), a clinical-stage cancer immunotherapy corporation, presented preliminary data from the Phase 1/2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in 10 patients with HPV-associated locally advanced anal cancer indicating that all patients who have accomplished treatment in the study have had a complete response with no evidence of recurrence to date (follow-up ranging from 0.5 — 24 months). The preliminary data also show that the investigational immunotherapy was well tolerated by the treated patients, and all treatment-related toxicities were within 24 hours of dosing, the most frequent of which comprise chills/rigors, fever and nausea.
The data were highlighted in an oral presentation by Kimberly Perez, M.D., Assistant Professor of Medicine at the Alpert Medical School, Brown University, during the recent International Anal Neoplasia Society (IANS) Scientific Meeting 2015, in Atlanta, Georgia.
Dr. Perez stated, “Though preliminary, the data we have observed thus far are extremely encouraging as all treated patients enrolled since April 2013 have had a complete response with no recurrence of the cancer. ADXS-HPV has the potential to be an important advancement in the treatment of HPV-associated anal cancer, and we look forward to reporting the full safety and efficacy data set once all 25 patients have accomplished the dosing regimen.”
Advaxis is a clinical-stage biotechnology corporation developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology. The Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth.
Greif, Inc. (NYSE:GEF)
Formerly on March 3, The Board of Directors of Greif, Inc. (GEF), declared quarterly cash dividends of $0.42 per share of Class A Ordinary Stock and $0.63 per share of Class B Ordinary Stock.
The dividends are payable on April 1, 2015 to shareholders of record at close of business on March 19, 2015.
Greif is a world leader in industrial packaging products and services. The corporation produces steel, plastic, fibre, flexible, corrugated, and reconditioned containers, intermediate bulk containers, containerboard and packaging accessories, and provides blending, filling, packaging and industrial packaging reconditioning services for a wide range of industries.
ResMed Inc. (NYSE:RMD)
ResMed Inc. (RMD), declared data from two studies about sleep-disordered breathing (SDB) in chronic heart failure presented at the 64th Annual Scientific Sessions of the American College of Cardiology, from March 14th through 16th.
Sleep-disordered breathing encompasses a spectrum of breathing problems during sleep. The two most ordinary types of sleep apnea, a condition that results in repetitive pauses in breathing during sleep, are obstructive sleep apnea and central sleep apnea. In either situation, lack of oxygen causes the person to wake up to catch their breath and start breathing again, interrupting continuous sleep. This may occur multiple times in an hour.
ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and administration of respiratory disorders, with a focus on sleep-disordered breathing.
Akorn, Inc. (NASDAQ:AKRX)
On March 11, Akorn, Inc. (AKRX), declared several generic product launches that build on Akorn’s commitment to serve the corporation’s specialty generic customers and patients.
Adenosine Injection. Akorn launched Adenosine Injection, USP, 60 mg/20 mL in 20 mL vials and 90 mg/30mL in 30mL vials, on December 22, 2014. Akorn’s product is an AP-rated generic version of Astellas’ Adenoscan(R) Injection and is a pharmacologic stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
According to IMS Heath, sales of branded and generic versions of Adenosine Injection, USP, 60 mg/20 mL in 20 mL vials and 90 mg/30mL in 30mL vials were about $33 million for the 12 months ended January 31, 2015.
Dexmedetomidine Hydrochloride Injection. Akorn launched Dexmedetomidine Hydrochloride Injection, 200mcg/2mL single dose vials on March 3, 2015. Akorn’s product is an AP-rated generic version of Hospira’s Precedex(TM) Injection. Akorn’s Dexmedetomidine Hydrochloride Injection is a relatively selective alpha2-andrenergic agonist indicated for the sedation of non-intubated patients preceding to and/or during surgical and other procedures.
According to IMS Heath, sales of branded and generic versions of Dexmedetomidine Hydrochloride Injection were about $121 million for the 12 months ended January 31, 2015.
Akorn, Inc. manufactures and markets diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India where the corporation manufactures ophthalmic, injectable and specialty non-sterile pharmaceuticals.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
